Serum adropin levels are reduced in patients with inflammatory bowel diseases

Abstract Adropin is a novel peptide mostly associated with energy homeostasis and vascular protection. To our knowledge, there are no studies that investigated its relationship with inflammatory bowel diseases (IBD). The aim of this study was to compare serum adropin levels between 55 patients with...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Darko Brnić, Dinko Martinovic, Piero Marin Zivkovic, Daria Tokic, Ivana Tadin Hadjina, Doris Rusic, Marino Vilovic, Daniela Supe-Domic, Ante Tonkic, Josko Bozic
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/f88028686be6416dbea14b895faee203
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f88028686be6416dbea14b895faee203
record_format	dspace
spelling	oai:doaj.org-article:f88028686be6416dbea14b895faee2032021-12-02T17:52:33ZSerum adropin levels are reduced in patients with inflammatory bowel diseases10.1038/s41598-020-66254-92045-2322https://doaj.org/article/f88028686be6416dbea14b895faee2032020-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-66254-9https://doaj.org/toc/2045-2322Abstract Adropin is a novel peptide mostly associated with energy homeostasis and vascular protection. To our knowledge, there are no studies that investigated its relationship with inflammatory bowel diseases (IBD). The aim of this study was to compare serum adropin levels between 55 patients with IBD (30 Ulcerative colitis (UC) patients, 25 Crohn’s disease (CD) patients) and 50 age/gender matched controls. Furthermore, we explored adropin correlations with IBD severity scores, hsCRP, fecal calprotectin, fasting glucose and insulin levels. Serum adropin levels were significantly lower in patients with IBD in comparison with the control group (2.89 ± 0.94 vs 3.37 ± 0.60 ng/mL, P = 0.002), while there was no significant difference in comparison of UC patients with CD patients (P = 0.585). Furthermore, there was a negative correlation between adropin and fecal calprotectin (r = −0.303, P = 0.025), whereas in the total study population, we found a significant negative correlation with fasting glucose levels (r = −0.222, P = 0.023). A multivariable logistic regression showed that serum adropin was a significant predictor of positive IBD status when enumerated along with baseline characteristics (OR 0.455, 95% CI 0.251–0.823, P = 0.009). Our findings imply that adropin could be involved in complex pathophysiology of IBD, but further larger scale studies are needed to address these findings.Darko BrnićDinko MartinovicPiero Marin ZivkovicDaria TokicIvana Tadin HadjinaDoris RusicMarino VilovicDaniela Supe-DomicAnte TonkicJosko BozicNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 10, Iss 1, Pp 1-9 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Darko Brnić Dinko Martinovic Piero Marin Zivkovic Daria Tokic Ivana Tadin Hadjina Doris Rusic Marino Vilovic Daniela Supe-Domic Ante Tonkic Josko Bozic Serum adropin levels are reduced in patients with inflammatory bowel diseases
description	Abstract Adropin is a novel peptide mostly associated with energy homeostasis and vascular protection. To our knowledge, there are no studies that investigated its relationship with inflammatory bowel diseases (IBD). The aim of this study was to compare serum adropin levels between 55 patients with IBD (30 Ulcerative colitis (UC) patients, 25 Crohn’s disease (CD) patients) and 50 age/gender matched controls. Furthermore, we explored adropin correlations with IBD severity scores, hsCRP, fecal calprotectin, fasting glucose and insulin levels. Serum adropin levels were significantly lower in patients with IBD in comparison with the control group (2.89 ± 0.94 vs 3.37 ± 0.60 ng/mL, P = 0.002), while there was no significant difference in comparison of UC patients with CD patients (P = 0.585). Furthermore, there was a negative correlation between adropin and fecal calprotectin (r = −0.303, P = 0.025), whereas in the total study population, we found a significant negative correlation with fasting glucose levels (r = −0.222, P = 0.023). A multivariable logistic regression showed that serum adropin was a significant predictor of positive IBD status when enumerated along with baseline characteristics (OR 0.455, 95% CI 0.251–0.823, P = 0.009). Our findings imply that adropin could be involved in complex pathophysiology of IBD, but further larger scale studies are needed to address these findings.
format	article
author	Darko Brnić Dinko Martinovic Piero Marin Zivkovic Daria Tokic Ivana Tadin Hadjina Doris Rusic Marino Vilovic Daniela Supe-Domic Ante Tonkic Josko Bozic
author_facet	Darko Brnić Dinko Martinovic Piero Marin Zivkovic Daria Tokic Ivana Tadin Hadjina Doris Rusic Marino Vilovic Daniela Supe-Domic Ante Tonkic Josko Bozic
author_sort	Darko Brnić
title	Serum adropin levels are reduced in patients with inflammatory bowel diseases
title_short	Serum adropin levels are reduced in patients with inflammatory bowel diseases
title_full	Serum adropin levels are reduced in patients with inflammatory bowel diseases
title_fullStr	Serum adropin levels are reduced in patients with inflammatory bowel diseases
title_full_unstemmed	Serum adropin levels are reduced in patients with inflammatory bowel diseases
title_sort	serum adropin levels are reduced in patients with inflammatory bowel diseases
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/f88028686be6416dbea14b895faee203
work_keys_str_mv	AT darkobrnic serumadropinlevelsarereducedinpatientswithinflammatoryboweldiseases AT dinkomartinovic serumadropinlevelsarereducedinpatientswithinflammatoryboweldiseases AT pieromarinzivkovic serumadropinlevelsarereducedinpatientswithinflammatoryboweldiseases AT dariatokic serumadropinlevelsarereducedinpatientswithinflammatoryboweldiseases AT ivanatadinhadjina serumadropinlevelsarereducedinpatientswithinflammatoryboweldiseases AT dorisrusic serumadropinlevelsarereducedinpatientswithinflammatoryboweldiseases AT marinovilovic serumadropinlevelsarereducedinpatientswithinflammatoryboweldiseases AT danielasupedomic serumadropinlevelsarereducedinpatientswithinflammatoryboweldiseases AT antetonkic serumadropinlevelsarereducedinpatientswithinflammatoryboweldiseases AT joskobozic serumadropinlevelsarereducedinpatientswithinflammatoryboweldiseases
_version_	1718379206555992064

Serum adropin levels are reduced in patients with inflammatory bowel diseases

Ejemplares similares